PL425544A1 - Immunomodulation of cells from myeloid lineage as a therapy - Google Patents
Immunomodulation of cells from myeloid lineage as a therapyInfo
- Publication number
- PL425544A1 PL425544A1 PL42554418A PL42554418A PL425544A1 PL 425544 A1 PL425544 A1 PL 425544A1 PL 42554418 A PL42554418 A PL 42554418A PL 42554418 A PL42554418 A PL 42554418A PL 425544 A1 PL425544 A1 PL 425544A1
- Authority
- PL
- Poland
- Prior art keywords
- cells
- agonist
- myeloid lineage
- relates
- pharmaceutical composition
- Prior art date
Links
Abstract
Niniejsze zgłoszenie dotyczy sposobu zwiększania aktywności przeciwnowotworowej komórek linii mieloidalnej, obejmującego etapy kontaktowania komórek linii mieloidalnej z agonistą receptora Toll-podobnego (TLR) i agonistą receptora determinanty komórkowej 200 (CD200R). Zgłoszenie ponadto dotyczy komórek, które mogą być wytwarzane sposobem i kompozycji farmaceutycznej zawierającej komórki oraz zastosowania tych komórek lub kompozycji farmaceutycznej zawierającej komórki jako leku, a w szczególności do zastosowania w leczeniu nowotworu. Zgłoszenie dotyczy także zestawu obejmującego agonistę TLR i agonistę CD200R. Zgłoszenie dotyczy także kompozycji farmaceutycznej zawierającej agonistę TLR i agonistę CD200R.The present application relates to a method of increasing the anti-tumor activity of cells of the myeloid lineage comprising the steps of contacting the cells of the myeloid lineage with a Toll-like receptor (TLR) agonist and a cell determinant receptor 200 (CD200R) agonist. The application further relates to cells that can be produced by the method and to a pharmaceutical composition containing cells and the use of these cells or a pharmaceutical composition containing cells as a medicament, and in particular for use in the treatment of cancer. The application also relates to a kit comprising a TLR agonist and a CD200R agonist. The application also relates to a pharmaceutical composition comprising a TLR agonist and a CD200R agonist.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL42554418A PL425544A1 (en) | 2018-05-15 | 2018-05-15 | Immunomodulation of cells from myeloid lineage as a therapy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL42554418A PL425544A1 (en) | 2018-05-15 | 2018-05-15 | Immunomodulation of cells from myeloid lineage as a therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
PL425544A1 true PL425544A1 (en) | 2019-11-18 |
Family
ID=68536638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL42554418A PL425544A1 (en) | 2018-05-15 | 2018-05-15 | Immunomodulation of cells from myeloid lineage as a therapy |
Country Status (1)
Country | Link |
---|---|
PL (1) | PL425544A1 (en) |
-
2018
- 2018-05-15 PL PL42554418A patent/PL425544A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018015684A (en) | Compositions and methods for the depletion of cd117+cells. | |
PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
MX2019008208A (en) | Methods of treating cancer with anti-tim-3 antibodies. | |
WO2019084064A3 (en) | Compositions and methods for the depletion of cd117+ cells | |
MX2020013348A (en) | Dll3-cd3 bispecific antibodies. | |
MX2018015683A (en) | Compositions and methods for the depletion of cells. | |
WO2019084057A3 (en) | Compositions and methods for the depletion of cd117+ cells | |
MX2020013557A (en) | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof. | |
WO2018157171A3 (en) | Compositions, articles of manufacture and methods related to dosing in cell therapy | |
AU2017238218B2 (en) | Early intervention methods to prevent or ameliorate toxicity | |
MX2019015021A (en) | Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies. | |
WO2019006005A3 (en) | Methods and compositions for treating melanoma | |
MX2018012390A (en) | Selenium disulfide compositions for use in treating meibomian gland dysfunction. | |
AU2018341571A8 (en) | Therapeutic methods relating to HSP90 inhibitors | |
GB201201314D0 (en) | Composition | |
MX2019010382A (en) | Immunotherapeutic tumor treatment method using an interleukin-2 receptor alpha, beta-selective agonist in combination with adoptive cell transfer therapy. | |
MX2017005134A (en) | Treatment of cancer with immune stimulators. | |
EA201690680A1 (en) | COMBINED ANTI-TUMOR TREATMENT WITH THE APPLICATION OF MINICOLES, LOADED BY MEDICINE MEANS, AIMED USING THE BISPECIFIC LIGAND, AND INTERFERON-GAMMA | |
CR20220329A (en) | Anti-mertk antibodies and methods of use thereof | |
MX2020011254A (en) | Anti-bcma car-t-cells for plasma cell depletion. | |
MX2020012613A (en) | Compositions and uses thereof for treating disease or condition. | |
PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
CO2020006855A2 (en) | Compositions and methods for cd2 + cell depletion | |
WO2018053264A3 (en) | Klrg1 depletion therapy | |
MX2020005640A (en) | Humanized anti-liv1 antibodies for the treatment of breast cancer. |